Bonnie Liu

TL;DR: It is demonstrated that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context, which provides new insights into the therapeutic use of ATP- competitive RAF inhibitors.

TL;DR: This paper identified three highly distinct metabolic subtypes in pancreatic ductal adenocarcinoma (PDAC) using broad metabolite profiling, which corresponded to differences in cell sensitivity to inhibitors of glycolysis, glutamine metabolism, lipid synthesis, and redox balance.

TL;DR: The data suggest that tumors with acquired MEK inhibitor resistance remain dependent on the MAPK pathway and are therefore sensitive to inhibitors that act downstream of the mutated MEK target, and provide a rationale for cotargeting multiple nodes within theMAPK signaling cascade in K-ras mutant tumors to maximize therapeutic benefit for patients.

TL;DR: An index that aggregates expression levels of 10 genes involved in modulating the mitogen-activated protein kinase (MAPK) pathway performed as well or better than other more complicated, genome-based tools at predicting whether drugs that inhibit MAPK-related enzymes were active against tumor cell lines.

TL;DR: Optimization led to the identification of 3-methoxy pyrazolopyridines 17 and 19, potent, selective, and orally bioavailable agents that inhibited tumor growth in a mouse xenograft model driven by B-Raf(V600E) with no effect on body weight.